RxDoctor Payments Data

Norman Parnell

Family · Lucedale, MSNPI 1184961054

Payments from drug & device makers

$556in general payments, 2019–2025

Across 16 payments — averaging $34.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$274
  • Lilly USA, LLC$98
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$43
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$38
  • AbbVie$31
  • Novo Nordisk$31
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$556 in reported general payments places this provider in the 55th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$43,253
Medicare patients
155
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$41,783
MounjaroTirzepatide34$40,297
TrulicityDulaglutide28$31,319
LinzessLinaclotide15$13,963
Albuterol Sulfate HfaAlbuterol Sulfate39$1,471
Galantamine ErGalantamine Hbr11$1,262
Ezetimibe26$1,135
Ventolin HfaAlbuterol Sulfate12$660
Esomeprazole Magnesium17$645
Losartan Potassium91$631
Fluticasone Propionate64$605
Glipizide60$600
Omeprazole66$591
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav44$497
Atorvastatin Calcium72$491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$98$71,61662 claims
Novo NordiskOzempic$31$41,78339 claims
AbbVieLinzess$31$13,96315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,007 family providers in Mississippi.

Other family in Lucedale

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →